Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Want to cut your energy bills? Here’s how five experts are doing it 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
PORT WASHINGTON, N.Y., April 07, 2016 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Salvatore Guccione, President and CEO, will present at the Needham & Company Healthcare Conference on April 12, 2016 at 5:00 pm ET at the Westin New York Grand Central Hotel.
A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company’s website at www.aceto.com or http://wsw.com/webcast/needham76/acet.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the marketing, sale and distribution of Human Health products (finished dosage form generics and nutritional products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).
Investor Relations Contact: LHA Jody Burfening [email protected] (212) 838-3777
